Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.010 -0.030 (-1.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
31 32 33 34 35 36 37 38 Next >
Mid-Morning Market Update: Markets Open Higher; Big Lots Reports Downbeat Profit
Following the market opening Friday, the Dow traded up 0.30% to 35,320.11 while the NASDAQ rose 0.27% to 14,986.36. The S&P also rose, gaining 0.33% to 4,484.57. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
63 Biggest Movers From Yesterday
Gainers Support.com, Inc. (NASDAQ: SPRT) shares surged 41.1% to settle at $19.70 on Thursday on abnormally high volume. TSR, Inc. (NASDAQ: TSRI) shares rose 28.1% to close at $11... 
Via Benzinga
CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences on Behalf of Cassava Sciences Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
CASSAVA SHAREHOLDER ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why Traders Shouldn’t Bargain Hunt in Cassava Stock
Wall Street is notorious for its overreactions, but when it comes to SAVA stock's cratering, investors consider other historical precedents. 
Via InvestorPlace
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – SAVA
From The Rosen Law Firm, P.A.
Via Business Wire
As Allegations Swirl, Can Investors Still Count on Cassava Sciences Stock?
This once-promising biotech is now struggling to stay afloat. 
Via The Motley Fool
Exposures Product Safety
Better Biotech Stock: Cassava Sciences vs. Annovis Bio
It boils down to which company's clinical trial results look better for treating Alzheimer's at the moment. 
Via The Motley Fool
GameStop Continues To See Sky-High WallStreetBets Interest; AMC, BlackBerry, Alibaba, Palantir Are Other Top Trends
GameStop Corp. (NYSE:GME) continued to be the most-discussed ... 
Via Benzinga
54 Biggest Movers From Yesterday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares jumped 202.8% to settle at $46.33 on Wednesday after gaining over 11% on Tuesday. Regencell Bioscience recently... 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
CASSAVA INVESTOR ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
The Law Offices of Frank R. Cruz Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
SAVA Stock: Cassava Sciences Sinks Despite Countering Trial Data Allegations
Today, investors in Cassava Sciences and SAVA stock are seeing a lot of red, as investors digest a statement of concern filed yesterday. 
Via InvestorPlace
Exposures Product Safety
Mid-Afternoon Market Update: Dow Rises 100 Points; ScanSource Shares Surge Following Q4 Results
Toward the end of trading Wednesday, the Dow traded up 0.30% to 35,470.78 while the NASDAQ rose 0.12% to 15,038.45. The S&P also rose, gaining 0.28% to 4,498.64. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500, Nasdaq Extend Records on Delta Variant Decline
The S&P 500 Index and Nasdaq Composite are on the rise midday, extending yesterday's record closes and nabbing fresh intraday highs. 
Via Talk Markets
Topics Stocks
Exposures US Equities
2 Little-Known Nasdaq Stocks Making Big Moves Wednesday
Don't let these companies fly under your radar. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
SAVA Stock: The Allegations That Have Cassava Sciences Sinking Today
Shares of SAVA stock are crashing on Wednesday after allegations about Cassava Sciences' Alzheimer's disease treatment are being reviewed. 
Via InvestorPlace
The Law Offices of Frank R. Cruz Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Regencell Bioscience (NASDAQ:RGC) stock rose 100.19% to $30.63 during Wednesday's regular session. Regencell Bioscience's stock is trading at a volume of 8... 
Via Benzinga
Mid-Day Market Update: Gold Down 1%; Locust Walk Acquisition Shares Jump
Midway through trading Wednesday, the Dow traded up 0.20% to 35,435.82 while the NASDAQ rose 0.05% to 15,027.49. The S&P also rose, gaining 0.14% to 4,492.54. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
36 Stocks Moving In Wednesday's Mid-Day Session
Gainers Locust Walk Acquisition Corp. (NASDAQ: LWAC) shares jumped 188% to $25.34 after the company announced stockholders approved a business combination with eFFECTOR... 
Via Benzinga
Here's Why Cassava Sciences Is Having a Bad Day
The FDA received a citizen petition requesting a halt to clinical trials with the company's Alzheimer's disease candidate. 
Via The Motley Fool
Exposures Product Safety
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cassava Sciences, Inc. (SAVA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Mid-Morning Market Update: Markets Edge Higher; Dick's Sporting Goods Beats Q2 Views
Following the market opening Wednesday, the Dow traded up 0.07% to 35,389.32 while the NASDAQ rose 0.17% to 15,045.45. The S&P also rose, gaining 0.14% to 4,492.57. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Cassava Sciences Stock Shows Promise With Simufilam Trials Drawing Near
SAVA stock is up as the company announced the FDA has agreed on study protocols for Phase 3 clinical trials of Simufilam. 
Via InvestorPlace
Exposures Product Safety
Cassava Stock Plummets On Claims Of 'Data Manipulation' In Alzheimer's Testing
A shareholder firm called for the FDA to halt Cassava Sciences' studies in Alzheimer's disease, leading SAVA stock to plummet Wednesday. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2
...
31 32 33 34 35 36 37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.